Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California, San Francisco, California, 94143-0912, USA.
Department of Chemical and Biomolecular Engineering, University of California, Berkeley, California, 94720-1462, USA.
AAPS J. 2021 May 10;23(3):67. doi: 10.1208/s12248-021-00591-z.
Drug dosing decisions in clinical medicine and in introducing a drug to market for the past 60 years are based on the pharmacokinetic/clinical pharmacology concept of clearance. We used chemical reaction engineering models to demonstrate the limitations of presently employed clearance measurements based upon systemic blood concentration in reflecting organ clearance. The belief for the last 49 years that in vivo clearance is independent of the mechanistic model for organ clearance is incorrect. There is only one valid definition of clearance. Defining organ clearance solely on the basis of systemic blood concentrations can lead to drug dosing errors when drug effect sites reside either in an eliminating organ exhibiting incremental clearance or in a non-eliminating organ where intraorgan concentration is governed by transporter actions. Attempts to predict clearance are presently hampered by the lack of recognition that what we are trying to predict is a well-stirred model clearance.
在过去的 60 年中,临床药物学和药物上市的药物剂量决策一直基于药物动力学/临床药理学的清除率概念。我们使用化学反应工程模型证明了目前基于全身血液浓度的清除率测量在反映器官清除率方面的局限性。过去 49 年来,人们一直认为体内清除率与器官清除率的机制模型无关,这一观点是不正确的。清除率只有一个有效的定义。仅根据全身血液浓度来定义器官清除率,当药物作用部位位于表现出递增清除率的消除器官中或位于受转运体作用控制的非消除器官中时,可能会导致药物剂量错误。目前,由于缺乏对我们试图预测的是一个充分混合模型清除率的认识,因此对清除率的预测受到阻碍。